Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with tough cancer: drug may keep neuroblastoma at bay

NCT ID NCT07278674

Disease control Sponsor: Shanghai Children's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug eflornithine, taken as a pill after immunotherapy, can help prevent high-risk neuroblastoma from coming back in children. Twenty children under 18 who have completed standard treatment will take eflornithine for maintenance. Researchers will track how long they stay cancer-free and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
eflornithine
What this could lead to
If it works, this could help prevent relapse and improve survival in children with high-risk neuroblastoma after standard treatment.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply broadly. Side effects from eflornithine are possible and will be monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children with high-risk neuroblastoma

Ages

1 month to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. According to the International Neuroblastoma Risk Group Classification, it has been histologically diagnosed as high-risk NB. 2. Under the age of 18. 3. The disease assessment status is PR (via CT or MRI) and the bone marrow smear is negative. 4. If the residual mass is MIBG negative or MIBG positive and lacks FDG-PET affinity, it is considered evidence that the mass does not represent active disease. Subjects with stable residual tumor mass visible on CT/MRI will be included in the study. 5. Qualified hematological parameters and organ function; Refer to the CI CTC 4.0 adverse reaction grading standard of grade 2 and below. 6. Eflornithine needs to be activated within 120 days after the completion of previous treatment. Exclusion Criteria: 1. According to the International Neuroblastoma Risk Group Classification, it has been histologically diagnosed as non high risk NB. 2. Prior to enrollment, the disease assessment status was either progressive disease (PD) or relapse (via CT or MRI). 3. Positive bone marrow smear. 4. Hematological parameters and organ function are not qualified, according to the CI CTC 4.0 adverse reaction grading standard of grade 3 or above. 5. The guardian does not agree to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High-risk neuroblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

High-risk neuroblastoma

Contacts and locations

Locations

  • Ruijin Hospital Hainan Branch, affiliated with Shanghai Jiao Tong University School of Medicine and Children's Hospital of Shanghai, affiliated with Shanghai Jiao Tong University School of Medicine

    Hainan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.